Antibacterial treatment of pregnant women colonized by streptococcus group B

Abstract

Relevance. Streptococcus group B (GBS), Streptococcus agalactiae, are the causative agents of severe infections of the fetus and newborn child.

The aim of the study was to investigate the efficacy and safety of antibacterial therapy with the use of amoxicillin with clavulanic acid and josamycin pregnant women with GBS, as well as the impact of antibiotic therapy on perinatal outcomes.

Materials and methods. For isolation and identification of Streptococcus and Ureaplasma used bacteriological method of research. The article presents the results of a survey of 99 pregnant women, the urogenital tract, which are colonized by streptococcus group B (GBS) and Ureaplasma, during their pregnancy, delivery and perinatal outcomes.

Results. All women were divided into three groups: I group — 29 (29.3%) women, with the presence of GBS in the urogenital tract and treated during pregnancy amoxicillin with clavulanic acid, group II — 24 (24,2%) women with the presence of GBS and Ureaplasma treated during pregnancy josamycin, group III — 46 (46.5%) of women with available GBS, which antibacterial therapy during pregnancy was not conducted. Our results confirmed the data of foreign authors about the high frequency of complications of pregnancy and delivery in women colonized by Streptococcus group B who did not receive antibiotic therapy. Thus it often happened GBS colonization of the skin and mucous membranes of infants, develop in utero infection in children born to these mothers.

Conclusion. Upon detection of GBS in the urogenital tract of pregnant women is necessary to carry out antibacterial therapy for the prevention of complications of pregnancy, delivery and intrauterine infection of the fetus. Moreover, in the simultaneous detection of Streptococcus group B and Ureaplasma effective to schedule josamycin (wilprafen), which acts on both of the microorganism.

Keywords

Streptococcus group B / pregnancy / complications of pregnancy and childbirth / perinatal outcomes / antibacterial therapy / amoxicillin / josamycin

References

[1] 1.Kuleshevich EV, Savicheva AM, Arzhanova ON. Suvorov A. N. Distribution and genetic organization of pathogenicity island XII among the clinical strains of GBS. Molecular Genetics, Microbiology and Virology. 2013;28(1):15-9.

[2] 2.Оганян К.А. Течение и исход беременности при колонизации мочеполового тракта женщин стрептококками группы В и D: Дис. … канд. мед. наук. – СПб., 2008. [Oganjan KA. Techenie i ishod beremennosti pri kolonizacii mochepolovogo trakta zhenshhin streptokokkami gruppy V i D. [dissertation]. Saint Petersburg; 2008. (In Russ.)]

[3] 3.Тотолян А.А. Стрептококки группы В в патологии человека. – СПб.: Человек, 2009. [Totoljan AA. Streptokokki gruppy V v patologii cheloveka. Saint Petersburg: Chelovek; 2009. (In Russ.)]

[4] 4.Оганян К.А., Аржанова О.Н., Савичева А.М. Профилактическое назначение антибактериальных препаратов беременным женщинам, колонизированным стрептококками группы В // Журнал акушерства и женских болезней. – 2015. – № 2. – С. 59–63. [Oganjan KA, Arzhanova ON, Savicheva AM. Prophylactic antimicrobial drugs to pregnant women colonized with group B streptococcus. Journal of Obstetrics and Women’s Diseases. 2015;(2):59-63. (In Russ.)]

[5] 5.Ohlsson A, Shah VS. Intrapartum antibiotics for known maternal Group B streptococcal colonization. Cochrane Database Syst Rev. 2014;(6):CD007467. doi: 10.1002/14651858.CD007467.pub4.

[6] 6.Six A, Joubrel C, Tazi A, Poyart C. Maternal and perinatal infections to Streptococcus agalactiae. Presse Med. 2014;43(6Pt1):706-14. doi: 10.1016/j.lpm.2014.04.008.

[7] 7.Baker CJ. Group B streptococcal infections. In: In infectious diseases of the fetus and newborn infant. 3rd ed. Philadelphia; 2004:980-1054.

[8] 8.Provisional Recommendations for the Prevention of Perinatal Group B Streptococcal Disease Date of posting of provisional recommendations. Guidelines in CDC Morb. and Mortal. Wkly Rep. 2010.

[9] 9.Mahieu L, Langhendries JP, Cossey V, et al. Management of the neonate at risk for early-onset Group B streptococcal disease (GBS EOD): new paediatric guidelines in Belgium. Acta Clin Belg. 2014;69(5):313-319. doi: 10.1179/2295333714Y. 0000000054.

RIGHTS & PERMISSIONS

Ohanyan K.A., Arzhanova O.N., Paykacheva J.M., Zatsiorsky S.L.